Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 71(3):209–11. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. Cancer J Clin. 68(1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot J-M, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase ii study. J Clin Oncol. 2012 10;30(17):2046–2054. doi:10.1200/JCO.2011.38.4032.
   PubMed Web of Science ®Google Scholar
• Dy G, Reungwetwattana T. 2013. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 12(1):22. doi:10.4103/1477-3163.123972.
   PubMedGoogle Scholar
• Hirsh V. 2010. Targeted therapies in metastatic non-small cell lung cancer (NSCLC): the rational approach. Oncol. 17(2):13–23. doi:10.3747/co.v17i2.549.
   Google Scholar
• Kim ES, Adv Exp Med Biol, 2016;893:189–209. doi: 10.1007/978-3-319-24223-1_10.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity. 39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Romano E, Romero P. 2015. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J ImmunoTher Cancer. 3(1):15. doi:10.1186/s40425-015-0059-z.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. 2017. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 9(11):913–927. doi:10.2217/imt-2017-0052.
   PubMed Web of Science ®Google Scholar
• Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, et al. 2014. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 6(2):523–532. doi:10.4161/mabs.27398.
   PubMed Web of Science ®Google Scholar
• McEarchern J, Smith L, McDonagh C, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. 2008;14(23):7763–7772. doi:10.1158/1078-0432.CCR-08-0493.
   Google Scholar
• Flieswasser T, Camara-Clayette V, Danu A, Bosq J, Ribrag V, Zabrocki P, Van Rompaey L, de Haard H, Zwaenepoel K, Smits E, et al.Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform ihc methodology as potential patient stratification method.2019 Oct 22.1110:1611.10.3390/cancers11101611. Clin Cancer Res.
   Google Scholar
• Rottey S, De Meulenaere A, Deron P, Ferdinande LFront Pharmacol.2017;10.3389/conf.fphar.2017.62.00003.
   Google Scholar
• Flieswasser T, Van Loenhout J, Freire Boullosa L, Van den Eynde A, De Waele J, Van Audenaerde J, Lardon F, Smits E, Pauwels P, Jacobs J. 2020. Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer. Cells. 9(6):1474. doi:10.3390/cells9061474.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, Hermans C, Smits E, Van Schil P, Lardon F, et al. 2015. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget. 6(15):13462–13475. doi:10.18632/oncotarget.3880.
   PubMedGoogle Scholar
• Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, Cuypers B, Laukens K, Bartholomeus E, Siozopoulou V, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. 2021;42:101949. doi:10.1016/j.redox.2021.101949
   Google Scholar
• Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, et al. 2017. Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. Oncotarget. 8(43):74058–74067. doi:10.18632/oncotarget.18202.
   PubMedGoogle Scholar
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K-Y, Ferrone S, Gameiro SR. 2013. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 133(3):624–636. doi:10.1002/ijc.28070.
   PubMed Web of Science ®Google Scholar
• Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. 2019;40(2):142–158. doi:10.1016/j.it.2018.12.003.
   Google Scholar
• Bryceson YT, March ME, Ljunggren H-G, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 2006;214(1):73–91. doi:10.1111/j.1600-065X.2006.00457.x.
   Google Scholar
• Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, et al. 2016. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget. 7(1):255–265. doi:10.18632/oncotarget.6353.
   PubMedGoogle Scholar
• Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. 2019. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer. Oncol Rep. 42(2):839–848. doi:10.3892/or.2019.7185.
   PubMed Web of Science ®Google Scholar
• Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M. 2016. MHC class I chain-related molecule a and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Immunother. 65(5):499–509. doi:10.1007/s00262-016-1814-9.
   Web of Science ®Google Scholar
• Merritt RE, Mahtabifard A, Yamada RE, Crystal RG, Korst RJ. 2003. Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg. 126(5):1609–1617. doi:10.1016/s0022-5223(03)00707-4.
   PubMed Web of Science ®Google Scholar
• Jiang S, Liu Z, Wu L, Yuan Y, Hu Y, Zhang X, Wei L, Zu Y. Tumor targeting with docosahexaenoic acid-conjugated docetaxel for inhibiting lung cancer metastasis to bone. 2018;16(3):2911–2920. doi:10.3892/ol.2018.9047.
   Google Scholar
• Lee YS, Radford KJ, Int Rev Cell Mol Biol, 2019;348:123–178. doi: 10.1016/bs.ircmb.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I. 2017. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Oncol. 28:xii44–55. doi:10.1093/annonc/mdx727.
   Google Scholar
• Van Audenaerde JR, Marcq E, Scheidt B, Davey AS, Oliver AJ, De Waele J, Quatannens D, Van Loenhout J, Pauwels P, Roeyen G, et al. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Transl Immunol. 2020 Aug 15;9(8):e1165. doi:10.1002/cti2.1165.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang S, Liu Y. 2015. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Rep. 5(1):15179. doi:10.1038/srep15179.
   Google Scholar
• Baras AS, Drake C, Liu J-J, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, et al. The ratio of CD8 to treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi:10.1080/2162402X.2015.1134412.
   PubMed Web of Science ®Google Scholar
• Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. 2018. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med. 16(1):86. doi:10.1186/s12967-018-1460-4.
   PubMedGoogle Scholar
• Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory t cells and promotes tumor growth. 2012;72(14):3664–3676. doi:10.1158/0008-5472.CAN-11-2791.
   Google Scholar
• Mack DG, Lanham AM, Palmer BE, Maier LA, Fontenot AP. 2009. CD27 expression on CD4+ T cells differentiates effector from regulatory t cell subsets in the lung. J Immunol. 182(11):7317–7324. doi:10.4049/jimmunol.0804305.
   PubMed Web of Science ®Google Scholar